May 30, 2023 | CARDIORENAL
1b) [email protected] will be sharing the algorithm he uses to treat #HFpEF based on evidence we have thus far and his anecdotal experience treating patients over the past 16 years in the @NMCardioVasc HFpEF Clinic.#CardioTwitter #MedEd @MedTweetorials #HeartFailure—...
May 30, 2023 | CARDIORENAL
2) Christos Argyropoulos MD, PhD @ChristosArgyrop is Division Chief, Nephrology @UNMHSC. #CKD is chronic #kidneydisease, #ESKD is end-stage kidney disease.#FOAMed #nephtwitter #cardiotwitter @MedTweetorials @NephUCommunity @ISNkidneycare @KidneyDiseaseFm...
May 23, 2023 | CARDIORENAL
2) Our expert author is Frederik H. Verbrugge @FH_Verbrugge Cardiology & ICU @HeartBrussels @UZBrussel | Research @MayoClinicCV | Deputy Editor EHJ ACVC | Editorial Consultant JACC Heart Fail. We are honoured to have him join our august faculty–see...
May 9, 2023 | CARDIORENAL
1b) [email protected] will be reviewing the mechanism of action #MOA of #mineralocorticoid receptor antagonists #MRAs in potential #renoprotection for pts with #CKD. He will also address the differences between #steroidal and #nonsteroidal MRA therapies...
Apr 20, 2023 | CARDIORENAL
2) This #tweetorial is supported by an unrestricted educational grant from Bayer and is intended for healthcare providers.— cardio-met (@cardiomet_CE) April 20, 2023 4) How do we know which pts with #T2D are at risk for #CKD? @AmDiabetesAssn & @goKDIGO...
Mar 13, 2023 | CARDIORENAL
2) This #accredited #tweetorial series on #kidneydisease #CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based based HCPs. Accreditation statement & faculty disclosures at...